

NAME	: Mr. ROOPESH S	MR NO.	: 23030654
AGE/SEX	: 41 Yrs / Male	VISIT NO.	: 171746
REFERRED BY	:	DATE OF COLLECTION	: 25-03-2023 at 08:36 AM
REF CENTER	: MEDIWHEEL	DATE OF REPORT	: 25-03-2023 at 02:11 PM



TEST PARAMETER	RESULT	REFERENCE RANGE	SPECIMEN
----------------	--------	-----------------	----------

HAEMATOLOGY

COMPLETE BLOOD COUNT (CBC) WITH ESR

Automated Cell Counter

HAEMOGLOBIN <i>Colorimetric Method</i>	15.9 gm/dL	13 - 18 gm/dL
HEMATOCRIT (PCV) <i>Calculated</i>	45.5 %	40 - 54 %
RED BLOOD CELL (RBC) COUNT <i>Electrical Impedance</i>	5.0 million/cu.mm	4.5 - 5.9 million/cu.mm
PLATELET COUNT <i>Electrical Impedance</i>	4.0 Lakhs/cumm	1.5 - 4.5 Lakhs/cumm
MEAN CELL VOLUME (MCV) <i>Calculated</i>	91.9 fl	80 - 100 fl
Note : All normal and abnormal platelet counts are cross checked on peripheral smear.		
MEAN CORPUSCULAR HEMOGLOBIN (MCH) <i>Calculated</i>	32.1 pg	26 - 34 pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) <i>Calculated</i>	35.0 %	31 - 35 %
TOTAL WBC COUNT (TC) <i>Electrical Impedance</i>	10370.0 cells/cumm	4000 - 11000 cells/cumm
NEUTROPHILS <i>VCS Technology/Microscopic</i>	68 %	40 - 75 %
LYMPHOCYTES <i>VCS Technology/Microscopic</i>	23 %	25 - 40 %
DIFFERENTIAL COUNT		
EOSINOPHILS <i>VCS Technology/Microscopic</i>	03 %	0 - 7 %
MONOCYTES <i>VCS Technology/Microscopic</i>	06 %	1 - 8 %
BASOPHILS <i>Electrical Impedance</i>	00 %	
ESR <i>Westergren Method</i>	07 mm/hr	0 - 15 mm/hr
BLOOD GROUP & Rh TYPING <i>Tube Agglutination (Forward and Reverse)</i>	"O" Positive	

Krishna M.



A. Vamseedhar

Dr. KRISHNA MURTHY

MD
BIOCHEMIST

Lab Seal

Dr. VAMSEEDHAR.A

D.C.P, M.D
CONSULTANT PATHOLOGIST

NAME	: Mr. ROOPESH S	MR NO.	: 23030654
AGE/SEX	: 41 Yrs / Male	VISIT NO.	: 171746
REFERRED BY	:	DATE OF COLLECTION	: 25-03-2023 at 08:36 AM
REF CENTER	: MEDIWHEEL	DATE OF REPORT	: 25-03-2023 at 02:11 PM



TEST PARAMETER	RESULT	REFERENCE RANGE	SPECIMEN
----------------	--------	-----------------	----------

GLYCATED HAEMOGLOBIN (HbA1C)
HPLC

4.8 %

American Diabetic Association (ADA) recommendations:

Non diabetic adults : <5.7 %

At risk (Pre diabetic): 5.7 – 6.4%

Diabetic : >= 6.5%

Therapeutic goal for glycemic control :

Goal for therapy: < 7.0%

Action suggested: > 8.0%


ESTIMATED AVERAGE GLUCOSE (eAG)
Calculation

91.06 mg/dL

Comments:

This assay is useful for diagnosing Diabetes and evaluating long term control of blood glucose concentrations in diabetic patients. It reflects the mean glucose concentration over the previous period of 8 to 12 weeks and is a better indicator of long term glycemic control as compared with blood and urine glucose measurements. This provides a additional criterion for assessing glucose control because glycated hemoglobin values are free of day-to-day glucose fluctuation and are unaffected by exercise or food ingestion.

After a sudden alteration in blood glucose concentration, the rate of change of HbA1c is rapid during initial 2 months, followed by more gradual change approaching steady state 3 months later.




Dr. KRISHNA MURTHY

MD
BIOCHEMIST



Lab Seal



Dr. VAMSEEDHAR.A

D.C.P, M.D
CONSULTANT PATHOLOGIST

Diagnosics & Speciality Centre

NAME :	Mr. ROOPESH S	MR NO. :	23030654
AGE/SEX :	41 Yrs / Male	VISIT NO. :	171746
REFERRED BY :		DATE OF COLLECTION :	25-03-2023 at 08:36 AM
REF CENTER :	MEDIWHEEL	DATE OF REPORT :	25-03-2023 at 02:11 PM



TEST PARAMETER	RESULT	REFERENCE RANGE	SPECIMEN
----------------	--------	-----------------	----------

CLINICAL BIOCHEMISTRY

LIVER FUNCTION TEST (LFT)

Spectrometry

TOTAL BILIRUBIN <i>Colorimetric Diazo Method</i>	0.51 mg/dL	0.2 - 1.2 mg/dL
---	------------	-----------------

DIRECT BILIRUBIN <i>Colorimetric Diazo Method</i>	0.05 mg/dL	0 - 0.4 mg/dL
--	------------	---------------

INDIRECT BILIRUBIN <i>Calculation</i>	0.46 mg/dl	0.2 - 0.8 mg/dl
--	------------	-----------------

S G O T (AST) <i>IFCC Without Pyridoxal Phosphates</i>	31 U/L	up to 35 U/L
---	--------	--------------

S G P T (ALT) <i>IFCC Without Pyridoxal Phosphates</i>	24.9 U/L	up to 50 U/L
---	----------	--------------

ALKALINE PHOSPHATASE <i>p-Nitrophenyl Phosphate</i>	101 U/L	36 - 113 U/L
--	---------	--------------

SERUM GAMMA GLUTAMYLTRANSFERASE (GGT) <i>GCNA-IFCC</i>	32.1 U/L	15 - 85 U/L
--	----------	-------------

TOTAL PROTEIN <i>Biuret Colorimetric</i>	6.40 g/dl	6.2 - 8 g/dl
---	-----------	--------------

S.ALBUMIN <i>Bromocresol Green (BCG)</i>	3.93 g/dl	3.5 - 5.2 g/dl
---	-----------	----------------

S.GLOBULIN <i>Calculation</i>	2.5 g/dl	2.5 - 3.8 g/dl
----------------------------------	----------	----------------

A/G RATIO <i>Calculation</i>	1.6	1 - 1.5
---------------------------------	-----	---------

POST PRANDIAL BLOOD SUGAR <i>Hexokinase</i>	123.5 mg/dl	80 - 150 mg/dl
--	-------------	----------------

BLOOD UREA <i>UREASE-GLUTAMATE DEHYDROGENASE (GLDH)</i>	16 mg/dL	15 - 50 mg/dL
--	----------	---------------

CREATININE <i>Jaffe Kinetic</i>	0.82 mg/dL	0.4 - 1.4 mg/dL
------------------------------------	------------	-----------------

URIC ACID <i>Uricase-Peroxidase</i>	3.7 mg/dL	3 - 7.2 mg/dL
--	-----------	---------------

SERUM ELECTROLYTES

SODIUM <i>Ion Selective Electrode (ISE)</i>	136 mmol/L	136 - 145 mmol/L
--	------------	------------------

POTASSIUM <i>Ion Selective Electrode (ISE)</i>	3.95 mmol/L	3.5 - 5.2 mmol/L
---	-------------	------------------

CHLORIDE <i>Ion Selective Electrode (ISE)</i>	104 mmol/L	97 - 111 mmol/L
--	------------	-----------------

Krishna M.



A. Vamseedhar

Dr. KRISHNA MURTHY

MD
BIOCHEMIST

Lab Seal

Dr. VAMSEEDHAR.A

D.C.P, M.D
CONSULTANT PATHOLOGIST

NAME : Mr. ROOPESH S	MR NO. : 23030654
AGE/SEX : 41 Yrs / Male	VISIT NO. : 171746
REFERRED BY :	DATE OF COLLECTION : 25-03-2023 at 08:36 AM
REF CENTER : MEDIWHEEL	DATE OF REPORT : 25-03-2023 at 02:11 PM



TEST PARAMETER	RESULT	REFERENCE RANGE	SPECIMEN
----------------	--------	-----------------	----------

LIPID PROFILE TEST

Spectrometry

TOTAL CHOLESTEROL
Cholesterol Oxidase-Peroxidase (CHOD-POD)

178 mg/dL

up to 200 mg/dL
Border Line: 200 – 240 mg/dL
High: > 240 mg/dL

TRIGLYCERIDES
Glycerol Peroxidase-Peroxidase (GPO-POD)

172.9 mg/dL

up to 150 mg/dL
Desirable: <150 mg/dL
Border Line: 150 – 200 mg/dL
High: >200 – 500 mg/dL
Very High: > 500 mg/dL

HDL CHOLESTEROL - DIRECT
PEG-Cholesterol Esterase

35.8 mg/dl

40 - 60 mg/dl
>= 60mg/dL - Excellent (protects against heart disease)
40-59 mg/dL - Higher the better
<40 mg/dL - Lower than desired (major risk for heart disease)

LDL CHOLESTEROL - DIRECT
Cholesterol Esterase-Cholesterol Oxidase

107.6 mg/dL

up to 100 mg/dL
100-129 mg/dL- Near optimal/above optimal
130-159 mg/dL- Borderline High
160-189 mg/dL- High
190->190 mg/dL - Very High

VLDL CHOLESTEROL
Calculation

34.6 mg/dL

2 - 30 mg/dL

TOTAL CHOLESTROL/HDL RATIO
Calculation

5.0

up to 3.5
3.5-5.0 - Moderate
>5.0 - High

LDL/HDL RATIO
Calculation

3.0

up to 2.5
2.5-3.3 - Moderate
>3.3 - High

FASTING BLOOD SUGAR
Hexokinase

95 mg/dl

70 - 110 mg/dl

Krishna M.



A. Vamseedhar

Dr. KRISHNA MURTHY

MD
BIOCHEMIST

Lab Seal

Dr. VAMSEEDHAR.A

D.C.P, M.D
CONSULTANT PATHOLOGIST

NAME : Mr. ROOPESH S	MR NO. : 23030654
AGE/SEX : 41 Yrs / Male	VISIT NO. : 171746
REFERRED BY :	DATE OF COLLECTION : 25-03-2023 at 08:36 AM
REF CENTER : MEDIWHEEL	DATE OF REPORT : 25-03-2023 at 02:11 PM



TEST PARAMETER	RESULT	REFERENCE RANGE	SPECIMEN
----------------	--------	-----------------	----------

CLINICAL PATHOLOGY

URINE ROUTINE & MICROSCOPIC

Strips & Microscopy

PHYSICAL EXAMINATION

Colour <i>Visual Method</i>	Pale Yellow	Pale yellow- yellow
Appearance <i>Visual Method</i>	Slightly Turbid	Clear/Transparent
Specific Gravity <i>Strips Method</i>	1.005	1.005-1.035
pH	6.0	4.6-8.5

CHEMICAL EXAMINATION (DIPSTICK)

Protein <i>Strips Method</i>	Nil	Nil -Trace
Glucose <i>Strips Method</i>	Nil	Nil
Blood <i>Strips Method</i>	Negative	Negative
Ketone Bodies <i>Strips Method</i>	Absent	Negative
Urobilinogen <i>Strips Method</i>	Normal	Normal
Bile Salt <i>Strips Method</i>	Negative	Negative
Bilirubin <i>Strips Method</i>	Negative	Negative
Bile Pigments	Negative	NIL

MICROSCOPY

Pus Cells (WBC) <i>Light Microscopic</i>	6 - 8 /hpf	0-5/hpf
Epithelial Cells <i>Light Microscopic</i>	3 - 4 /hpf	0-4/hpf
RBC <i>Light Microscopic</i>	Not Seen /hpf	0-2/hpf
Cast <i>Light Microscopic</i>	NIL	NIL
Crystal <i>Light Microscopic</i>	NIL	Nil

FASTING URINE SUGAR (FUS)	NIL	NIL
---------------------------	-----	-----

Krishna M. Murthy



A. Vamseedhar

Dr. KRISHNA MURTHY

MD
BIOCHEMIST

Lab Seal

Dr. VAMSEEDHAR.A

D.C.P, M.D
CONSULTANT PATHOLOGIST

NAME	: Mr. ROOPESH S	MR NO.	: 23030654
AGE/SEX	: 41 Yrs / Male	VISIT NO.	: 171746
REFERRED BY	:	DATE OF COLLECTION	: 25-03-2023 at 08:36 AM
REF CENTER	: MEDIWHEEL	DATE OF REPORT	: 25-03-2023 at 02:11 PM



TEST PARAMETER	RESULT	REFERENCE RANGE	SPECIMEN
POSTPRANDIAL URINE SUGAR	NIL	NIL	

IMMUNOASSAY

THYROID PROFILE


TOTAL TRIIODOTHYRONINE (T3) <small>CMA</small>	1.15 ng/mL	0.87 - 1.78 ng/mL
TOTAL THYROXINE (T4) <small>CMA</small>	11.79 µg/dL	6.09 - 12.23 µg/dL
THYROID STIMULATING HORMONE (TSH) <small>CMA</small>	2.280 µIU/mL	0.38 - 5.33 µIU/mL 1st Trimester: 0.05 - 3.70 2nd Trimester: 0.31 - 4.35 3rd Trimester: 0.41 - 5.18

Note:

- TSH levels are subject to circadian variation, reaching peak levels between 2 - 4 a.m. and at a minimum between 6-10 pm. The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
- Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

Clinical Use:

- Primary Hypothyroidism
- Hyperthyroidism
- Hypothalamic - Pituitary hypothyroidism
- Inappropriate TSH secretion
- Nonthyroidal illness
- Autoimmune thyroid disease
- Pregnancy associated thyroid disorders
- Thyroid dysfunction in infancy and early childhood




Dr. KRISHNA MURTHY

MD
BIOCHEMIST



Lab Seal



Dr. VAMSEEDHAR.A

D.C.P, M.D
CONSULTANT PATHOLOGIST

NAME	: Mr. ROOPESH S	MR NO.	: 23030654
AGE/SEX	: 41 Yrs / Male	VISIT NO.	: 171746
REFERRED BY	:	DATE OF COLLECTION	: 25-03-2023 at 08:36 AM
REF CENTER	: MEDIWHEEL	DATE OF REPORT	: 25-03-2023 at 02:11 PM



TEST PARAMETER	RESULT	REFERENCE RANGE	SPECIMEN
----------------	--------	-----------------	----------

PROSTATIC SPECIFIC ANTIGEN (PSA)

ECLIA

PROSTATIC SPECIFIC ANTIGEN (PSA)

CMA

1.10 ng/mL

Up to 4ng/mL: Normal
4-10 ng/mL Hypertrophy &
benign genito urinary
conditions.
>10 ng/mL Suspicious of
malignancy.

PSA is used for monitoring patients with a history of prostate cancer and as an early indicator of recurrence and response to treatment. The test is commonly used for Prostate cancer screening.

Dispatched by: KIRAN

**** End of Report ****

Printed by: Kiran kumar H P on 25-03-2023 at 02:12 PM



Krishna M.



A. Vamseedhar

Dr. KRISHNA MURTHY

MD
BIOCHEMIST

Lab Seal

Dr. VAMSEEDHAR.A

D.C.P, M.D
CONSULTANT PATHOLOGIST

NAME : **Mr. ROOPESH S**
AGE/SEX : 41 Yrs / Male
REFERRED BY :
REF CENTER : MEDIWHEEL

MR/VISIT NO : 23030654 / 171746
BILLED TIME : 25-03-2023 at 08:29 AM
BILL NO : 203657
DATE OF REPORT : 25-03-2023 at 11:03 AM

RADIOLOGY

X-RAY REPORT- CHEST (PA VIEW)

OBSERVATIONS:

The lung fields are clear bilaterally.

CP angles are clear.

Both the hila appear normal.

Cardiac diameter is within normal limits.

Trachea is midline.

Visible bony thoracic cage is normal.

Adjacent soft tissues appear normal.

Fat pad noted causing blunting of bilateral cardio phrenic angle.

IMPRESSION:

- **No significant abnormality in the visualized lung fields.**



NAME : **Mr. ROOPESH S**
AGE/SEX : 41 Yrs / Male
REFERRED BY :
REF CENTER : MEDIWHEEL

MR/VISIT NO : 23030654 / 171746
BILLED TIME : 25-03-2023 at 08:29 AM
BILL NO : 203657
DATE OF REPORT : 25-03-2023 at 11:03 AM

RADIOLOGY

X-RAY REPORT- CHEST (PA VIEW)

OBSERVATIONS:

The lung fields are clear bilaterally.

CP angles are clear.

Both the hila appear normal.

Cardiac diameter is within normal limits.

Trachea is midline.

Visible bony thoracic cage is normal.

Adjacent soft tissues appear normal.

Fat pad noted causing blunting of bilateral cardio phrenic angle.

IMPRESSION:

- **No significant abnormality in the visualized lung fields.**



NAME : **Mr. ROOPESH S**
AGE/SEX : 41 Yrs / Male
REFERRED BY :
REF CENTER : MEDIWHEEL

MR/VISIT NO : 23030654 / 171746
BILLED TIME : 25-03-2023 at 08:29 AM
BILL NO : 203657
DATE OF REPORT : 25-03-2023 at 03:23 PM

RADIOLOGY

USG REPORT - ABDOMEN AND PELVIS

OBSERVATION:

LIVER:

Liver is enlarged in size (17.1 cm) and shows mild diffuse increase in echotexture. No obvious focal lesion is seen. Intrahepatic biliary radicles not dilated. Hepatic and portal veins are normal. CBD is normal.

GALL BLADDER:

Normal in distension. Lumen echo free. Wall thickness is normal.

PANCREAS:

Head and body visualized appears normal. No focal lesion is seen. Pancreatic duct not dilated. Tail not visualized.

SPLEEN:

Normal in size (11.7 cm) with homogenous echotexture. No focal lesion seen.

RIGHT KIDNEY:

Right kidney measures ~ 10.5 x 1.3 cm (length x parenchymal thickness) with normal echo pattern and cortical thickness.

The shape, size and contour of the right kidney appear normal.

Cortico- medullary differentiation is maintained.

No evidence of pelvicalyceal dilatation. No sonologically detectable calculi seen.

LEFT KIDNEY:

Left kidney measures ~ 11.9 x 1.6 cm (length x parenchymal thickness) with normal echo pattern and cortical thickness.

The shape, size and contour of the left kidney appear normal.

Cortico-medullary differentiation is maintained.

No evidence of pelvicalyceal dilatation. No sonologically detectable calculi seen.

NAME	: Mr. ROOPESH S	MR/VISIT NO	: 23030654 / 171746
AGE/SEX	: 41 Yrs / Male	BILLED TIME	: 25-03-2023 at 08:29 AM
REFERRED BY	:	BILL NO	: 203657
REF CENTER	: MEDIWHEEL	DATE OF REPORT	: 25-03-2023 at 03:23 PM

URINARY BLADDER:

Is normal in contour. No intraluminal echoes are seen. No calculus or diverticulum is seen. Wall thickness appears normal.

PROSTATE:

Is normal in size (Volume – 21 cc) with normal echo pattern. No focal lesion is seen.

No evidence of free fluid in the pelvic or abdominal cavity.

IMPRESSION:

- **Hepatomegaly with grade I fatty changes.**
- **No other significant sonographic abnormality detected.**

Note: All abnormalities cannot be detected by Ultrasound scan due to technical limitation, obesity and other factors. Scan findings to be correlated with old reports or other investigations.

